While antitumor immunity in the steady state is not affected by the absence of DNGR-1, we find that genetic ablation or therapeutic blockade of DNGR-1 in the presence of Flt3L results in delayed tumor growth. The gene discussed is FLT3LG; the disease is neoplasm.